Sorted By:

Relevance


Why The War On Cancer Hasn't Been Won

From Hope To Cures  |  From Our Network

"The thought, at least in the early 1980s, was that were a small number of these mutant, cancer-causing oncogenes, and therefore that one could understand a whole disparate group of cancers simply by studying these mutant genes that seemed to be present in many of them," Weinberg says.
http://www.fromhopetocures.org/why-the-war-on-cancer-hasnt-been-won

Paul Aines

PhRMA  |  Biography

He started his career on the audit staff at professional services company KPMG LLP.
https://www.phrma.org/biography/paul-aines

Olivier Brandicourt

PhRMA  |  Biography

Brandicourt started his career as a Medical Director for the Region Africa at Warner-Lambert/Parke-Davis, where he held other senior positions in medical and marketing before being appointed General Manager of Canada.
https://www.phrma.org/biography/olivier-brandicourt

PhRMA Statement on 2014 Special 301 Report

PhRMA  |  Press Release

The Special 301 process garners the high-level attention from our trading partners necessary to redress intellectual property violations and market access concerns within individual markets and to send signals to other U.S. trading partners that protecting American intellectual property is important not only to the U.S. economy but also to patients across the globe.
https://www.phrma.org/press-release/phrma-statement-on-2014-special-301-report

I’m Not Average: Jack’s Journey Battling Rare Blood Cancer

PhRMA  |  Blog Post

He retired from his career as an IT research analyst and is now a patient advocate for others with rare diseases.
http://catalyst.phrma.org/im-not-average-jacks-journey-battling-rare-blood-cancer

Paul A. Aines Named PhRMA Executive Vice President and Chief Financial Officer; Del Persinger to Retire

PhRMA  |  Press Release

A recipient of a B.S. in Accounting from Virginia Tech and an M.B.A. from The George Washington University, Aines started his career on the audit staff at professional services company KPMG LLP.
https://www.phrma.org/press-release/paul-a-aines-named-phrma-executive-vice-president-and-chief-financial-officer-del-persinger-to-retire

New Chart Pack: Advancing Innovative Treatment Options for Patients Through Personalized Medicine

PhRMA  |  Blog Post

One of the most promising fields, personalized medicine (sometimes referred to as precision or individualized medicine), capitalizes on emerging scientific advances by using diagnostic tools to identify specific biological markers that can help direct prevention and treatment options for patients.
http://catalyst.phrma.org/new-chart-pack-advancing-innovative-treatment-options-for-patients-through-personalized-medicine

Amy Miller

PhRMA  |  Biography

She began her career as a researcher at National Institute of Child Health and Human Development.  
https://www.phrma.org/biography/amy-miller

Nobuhiko Tamura

PhRMA  |  Biography

Tamura began his career as a researcher at Sumitomo Chemical Co., Ltd. in 1982 and was one of the first employees of Sumitomo Pharmaceutical Co., Ltd.
https://www.phrma.org/biography/nobuhiko-tamura

Conversations Contributors - Marc M. Boutin, JD

PhRMA  |  Biography

Boutin has been actively involved in health advocacy, policy, and both federal and state legislation throughout his career.
https://www.phrma.org/biography/conversations-contributors-marc-m-boutin-jd

Brenton Saunders

PhRMA  |  Biography

Saunders began his career as chief compliance officer for the Thomas Jefferson University Health System.
https://www.phrma.org/biography/brenton-saunders

Senior Manager – Advocacy and Strategic Alliances

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.
https://www.phrma.org

ICER framework threatens to halt continued progress against multiple myeloma

PhRMA  |  Blog Post

Biopharmaceutical researchers hope that the 41 medicines in development for multiple myeloma could help increase the survival rate.
http://catalyst.phrma.org/icer-framework-threatens-to-halt-continued-progress-against-multiple-myeloma

Pediatrics

PhRMA  |  From PhRMA

BPCA has proven to be an effective incentive for stimulating pediatric drug development, especially in cases where PREA requirements do not apply (for example, for orphan diseases, including rare cancers).
https://www.phrma.org/pediatrics

The Science of Hope: Understanding biomarkers

PhRMA  |  Blog Post

Examples of biomarkers include using blood sugar levels to identify and monitor patients with diabetes, BRCA1/2 gene mutations to evaluate a patient’s risk of developing certain cancers, including breast and ovarian cancer, or viral load counts to evaluate a patient’s response to antiretroviral treatments.
http://catalyst.phrma.org/the-science-of-hope-understanding-biomarkers

Alzheimer’s Disease Clinical Trials

PhRMA  |  Report

-amyloid Compared to Histopathologyhttp://ClinicalTrials.gov/show/NCT01020838 Study 94 – RecruitingA Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Studyhttp://ClinicalTrials.gov/show/NCT01230853 Study 95 – RecruitingStudy of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairmenthttp://ClinicalTrials.gov/show/NCT01072812 Study 96 – Enrolling by invitationEvaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Open Label Extension (CT04 OLEP)http://ClinicalTrials.gov/show/NCT01421056 Study 97 – Enrolling by invitationEvaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phasehttp://ClinicalTrials.gov/show/NCT01602393 Study 98 – Active, not recruitingA Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])http://ClinicalTrials.gov/show/NCT01537757 Study 99 – RecruitingA Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjectshttp://ClinicalTrials.gov/show/NCT01221259 Study 100 – RecruitingTMS Stimulation and Cognitive Training in Alzheimer Patientshttp://ClinicalTrials.gov/show/NCT01168245 Study 101 – RecruitingAn Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Diseasehttp://ClinicalTrials.gov/show/NCT01325402 Study 102 – RecruitingAlzheimer and Sleephttp://ClinicalTrials.gov/show/NCT00750529 Study 103 – RecruitingEffects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patientshttp://ClinicalTrials.gov/show/NCT01504958 Study 104 – RecruitingClinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairmenthttp://ClinicalTrials.gov/show/NCT00149175 Study 105 – RecruitingClinical Evaluation of Florbetapir F 18 (18F-AV-45)http://ClinicalTrials.gov/show/NCT01518374 Study 106 – RecruitingA 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)http://ClinicalTrials.gov/show/NCT01429623 Study 107 – Active, not recruitingRosiglitazone Effects on Cognition for Adults in Later Lifehttp://ClinicalTrials.gov/show/NCT00242593 Study 108 – RecruitingThe Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairmenthttp://ClinicalTrials.gov/show/NCT00544791   * Source: www.clinicaltrials.gov; Search criteria: Alzheimer’s disease, Phase I, II, III; industry only. 
https://www.phrma.org

A voice for patients

PhRMA  |  Blog Post

Fortunately, the medical field gave me the opportunity to combine my two passions into one career.
http://catalyst.phrma.org/a-voice-for-patients

Medicare Monday: 3 things to know about the government’s Medicare payment change

PhRMA  |  Blog Post

As new medicines become available, especially new targeted and personalized medicines, like President Jimmy Carter’s recent cancer treatment, Medicare physicians and patients should have those options available to them.
http://catalyst.phrma.org/medicare-monday-3-things-to-know-about-the-governments-medicare-payment-change

Christopher Viehbacher Continues as PhRMA Board Chair; John Lechleiter, Robert Hugin Assume New Posts

PhRMA  |  Press Release

“As a scientist and as someone who has spent my entire career in the research-based biopharmaceutical industry, I know first-hand the importance of bringing new medicines to patients, and the challenges and complexity of making that a reality,” said Lechleiter.
https://www.phrma.org/press-release/christopher-viehbacher-continues-as-phrma-board-chair-john-lechleiter-robert-hugin-assume-new-posts

B Vitamin Is Found to Help People Prone to Some Types of Skin Cancer

From Hope To Cures  |  From Our Network

Most of these are curable through surgery or other techniques, though the surgery can leave scars and in some cases the cancers do become more serious.
http://www.fromhopetocures.org/b-vitamin-is-found-to-help-people-prone-to-some-types-of-skin-cancer

PhRMA Foundation Awards Comparative Effectiveness Grants

PhRMA  |  Press Release

  For 46 years, the PhRMA Foundation has supported the field of drug discovery and the careers of scientific investigators, faculty members and physicians.  
https://www.phrma.org/press-release/phrma-foundation-awards-comparative-effectiveness-grants

Glossary: Value of Personalized Medicine

Chartpack  |  From Our Network

Personalized Medicine: Sometimes referred to as precision or individualized medicine, personalized medicine, is an emerging field of medicine that uses diagnostic tools to identify specific biological markers, often genetic, to help assess which medical treatments and procedures will be best for each patient.
http://chartpack.phrma.org/personal-medicines-in-development-chartpack/advancing-policies-to-foster-innovation-sustaining-advances-in-personalized-medicine/glossary-value-of-personalized-medicine

O365 Senior Manager – Information Technology

PhRMA  |  PhRMA Career

We are committed to supporting our family of professionals at PhRMA and strive to create programs that help our team members manage the challenges of balancing a fast-paced career with their own personal goals.
https://www.phrma.org

Josephine Martin Joins PhRMA as Exec VP of Public Affairs

PhRMA  |  Press Release

Martin began her career on Capitol Hill, serving as communications director and press secretary for the Senate Finance Committee and Senator John Chafee.
https://www.phrma.org/press-release/josephine-martin-joins-phrma-as-exec-vp-of-public-affairs

Medicines in Development for Women 2013 Report

PhRMA  |  Report

The medicines in the pipeline for women (either in clinical trials or awaiting review by the Food and Drug Administration) include: 139 for cancers affecting women, including 91 for breast cancer, 49 for ovarian cancer and nine for cervical cancer.
https://www.phrma.org/report/medicines-in-development-for-women

You have reviewed the first 125 results out of 262. Each page contains 25 results. You're on page 5.

prev 1 2 3 4 5 6 next